Canadian Cancer Trials Group Bulletins

Trial Management Group


Canadian Cancer Trials Group MA.32 Closed to North American Accrual

The Canadian Cancer Trials Group is very pleased to announce that MA.32 - A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer - has reached its target accrual of 3582 patients and is now closed to accrual in North America.

The Canadian Cancer Trials Group is grateful to the approximately 300 participating sites for their tremendous interest and support. This support allowed MA.32 to reach its accrual target in less than 3 years!!

The next milestone will be the first interim analysis when 185 events have been confirmed.

Congratulations to all for helping to ensure the success of this trial.